ANXA9 as a novel prognostic biomarker associated with immune infiltrates in gastric cancer

Tongtong Zhang*, Suyang Yu* and Shipeng Zhao

Department of Gastrointestinal Surgery, The Third Hospital Affiliated to Hebei Medical University, Shijiazhuang, Hebei, China

* These authors contributed equally to this work.

ABSTRACT

Background: Gastric cancer (GC) is the most prevalent malignancy among the digestive system tumors. Increasing evidence has revealed that lower mRNA expression of ANXA9 is associated with a poor prognosis in colorectal cancer. However, the role of ANXA9 in GC remains largely unknown.

Material and Methods: The Gene Expression Profiling Interactive Analysis (GEPIA) and Human Protein Atlas databases were used to investigate the expression of ANXA9 in GC, which was then validated in the four Gene Expression Omnibus (GEO) datasets. The diagnostic value of ANXA9 for GC patients was demonstrated using a receiver operating characteristic (ROC) curve. The correlation between ANXA9 expression and clinicopathological parameters was analyzed in The Cancer Genome Atlas (TCGA) and UALCAN databases. The Kaplan-Meier (K-M) survival curve was used to elucidate the relationship between ANXA9 expression and the survival time of GC patients. We then performed a gene set enrichment analysis (GSEA) to explore the biological functions of ANXA9. The relationship of ANXA9 expression and cancer immune infiltrates was analyzed using the Tumor Immune Estimation Resource (TIMER). In addition, the potential mechanism of ANXA9 in GC was investigated by analyzing its related genes.

Results: ANXA9 was significantly up-regulated in GC tissues and showed obvious diagnostic value. The expression of ANXA9 was related to the age, gender, grade, TP53 mutation, and histological subtype of GC patients. We also found that ANXA9 expression was associated with immune-related biological function. ANXA9 expression was also correlated with the infiltration level of CD8+ T cells, neutrophils, and dendritic cells in GC. Additionally, copy number variation (VNV) of ANXA9 occurred in GC patients. Function enrichment analyses revealed that ANXA9 plays a role in the GC progression by interacting with its related genes.

Conclusions: Our results provide strong evidence of ANXA9 expression as a prognostic indicator related to immune responses in GC.

Keywords: Gastric cancer, ANXA9, Prognosis, Immune infiltrates, GEO, TCGA
INTRODUCTION

Gastric cancer (GC), a cause of some of the the deadliest tumors, is the fifth most common cancer worldwide and is most prevalent in East Asian countries, such as Korea, Mongolia, Japan and China, followed by Eastern Europe (Correa, 2016; Tsukanov et al., 2011). In 2015, there were an estimated 679,000 new GC cases and 498,000 deaths from GC in China (Chen et al., 2016). Despite many recent developments in the treatments of GC, including surgery, chemotherapy, radiation and immunotherapy, all of which can be used alone or in combination (Song et al., 2017), the 5-year survival rates of patients with high-grade GC remain poor, at just 30–35% (Miller et al., 2019; Chon et al., 2017). Moreover, despite substantial improvements in targeted therapies including HER2, EGFR1 and VEGF, there are still many limitations to these therapies (Kim, Mulder & Spratlin, 2014; Lordick et al., 2013; Maeda et al., 1996). Most patients with GC only demonstrate the clinical features of the disease in the advanced stage which is too late to receive effective therapy (Luebeck et al., 2013). Therefore, screening novel biomarkers to increase early diagnosis and treatment of GC is an urgent necessity.

The Annexin A (ANXA) family is known to be related to the progression of cancer (Boudhraa et al., 2016; Qi et al., 2015; Lauritzen, Boye & Nylandsted, 2015). Annexin A9 (ANXA9), initially known as annexin 31, is mainly involved in the organization and regulation of membrane/cytoskeleton linkage (Morgan et al., 1999), and is a protein encoding gene located in human chromosome 1q21 (Boczonadi & Määttä, 2012; Goebeler et al., 2003). ANXA9 is associated with relapse in both bone and breast cancers (Smid et al., 2006). Previous studies have also found that ANXA9 is a potential prognosis indicator for ER+ breast cancer and colorectal cancer (Xiao et al., 2019; Miyoshi et al., 2014; Yu et al., 2018). Furthermore, ANXA9 might be related to the invasion and metastasis of colorectal cancer through the regulation of ADAM17, MMP-9, TIMP-1 and E-cadherin (Yu et al., 2018). ANXA9 also participates in the pathogenesis of HPV-Negative head and neck squamous cell carcinomas (Salom et al., 2019), and plays a key role in the cisplatin-resistance of ovarian carcinoma cells (Kou et al., 2021). Importantly, ANXA9 has been discovered to be associated with the pathogenesis and maintenance of immunodeficiency in immunodeficient mice (Nakashima et al., 2019). Despite all these known associations, the potential role and mechanisms of ANXA9 in GC progression and immunology remain unclear.

In the present study, we aimed to systematically assess the role of ANXA9 in GC. First, the ANXA9 expression in GC was investigated using the data from the Cancer Genome Atlas (TCGA, https://portal.gdc.cancer.gov/) (Tomczak, Czerwińska & Wiznerowicz, 2015) and the Gene Expression Omnibus (GEO, https://www.ncbi.nlm.nih.gov/geo/) databases (Edgar, Domrachev & Lash, 2002). Next, we explored the correlations between ANXA9 expression and clinicopathologic features, prognosis and immune cell infiltration. We also analyzed the functions and regulating mechanisms of ANXA9. These analyses will help provide a better understanding of a possible molecular mechanism of GC and may help improve treatment for GC.
MATERIALS AND METHODS

Date acquisition and description

All the publicly available transcriptome data and clinical information of GC patients we used in this analysis was downloaded from the TCGA database. The TCGA transcriptome data comprised of 375 tumor tissue samples and 32 normal tissue samples.

Microarray series (GSE13861, GSE13911, GSE19826 and GSE79973) containing GC and normal samples were extracted from the GEO database. The GSE13861 dataset, based on the GPL6884 platform, contained 65 GC samples and 19 normal samples. GSE13911 is a microarray dataset that contained 38 patients with GC and 31 normal individuals. The GSE19826 dataset included 12 GC samples and 15 normal samples. A total of 20 samples were acquired from the GSE79973 dataset including 10 GC and 10 normal samples. The GSE13911, GSE19826, and GSE79973 datasets are all from the GPL570 platform.

Gene expression profiling interactive analysis (GEPIA) database analysis

GEPIA (http://gepia.cancer-pku.cn/) is an online database containing 9,736 tumors tissue samples and 8,587 normal tissue samples of the TCGA and Genotype-Tissue Expression (GTEx) databases (Tang et al., 2017). The expression of ANXA9 was examined in 33 different types of cancers within the “Single Gene Analysis” module of the GEPIA database. A P-value less than 0.05 was considered significant.

Validation of ANXA9 expression in the TCGA database and four GEO datasets

ANXA9 expression was further demonstrated in the TCGA database and four GEO datasets mentioned above. The Wilcoxon sign-ranked test (wilcox.test) was used to analyze the difference in the expression of ANXA9 between GC and normal tissue samples. By conducting the receiver operating characteristic (ROC) analysis with “survivalROC” R package to evaluate the diagnostic value discriminating GC from normal tissues (Heagerty, Lumley & Pepe, 2000), we calculated the area under the curve (AUC) of the ANXA9 expression level.

Human protein atlas

The The Human Protein Atlas (HPA) database (https://www.proteinatlas.org/) collected the tissue and cell distribution information of 26,000 human proteins (Asplund et al., 2012). In this study, the protein expression of ANXA9 in both GC and normal tissues were acquired from the HPA database.

UALCAN database analysis

The UALCAN database (http://ualcan.path.uab.edu) is a comprehensive web resource for analyzing TCGA gene expression data (Chandrashekar et al., 2017). We analyzed the relationship of ANXA9 expression and the clinicopathological characteristics of GC
patients with the UALCAN database. The differences of the different groups were compared using the Wilcox.test.

**Survival analysis**

After eliminating the 26 samples with missing clinical information, the remaining 349 GC patients in the TCGA database were ranked into two groups based on the expression of ANXA9—a ANXA9 high expression group and a ANXA9 low expression group. To analyze the overall survival (OS), 3-year survival rate, and 5-year survival rate of GC patients between the different groups, we performed the Kaplan-Meier (K-M) analysis with the log-rank test. Results where $P < 0.05$ were considered statistically significant.

**Functional enrichment analysis**

All the genes between the ANXA9 high and low expression groups were utilized to perform a gene set enrichment analysis (GSEA). The terms with a $P$ value $< 0.05$ were considered significantly enriched. The relative expression of 29 immune-related gene sets acquired from the literatures were calculated with single-sample gene set enrichment analysis (ssGSEA) in the “gsva” R package (Hänzelmann, Castelo & Guinney, 2013).

**Tumor immunity estimation resource (TIMER) database analysis**

The TIMER database is a comprehensive resource that we used for the systematic analysis of immune infiltration levels in different types of cancer (Li et al., 2017). The TIMER database contained macrophages CD4$^+$ T cells, B cells, neutrophils, CD8$^+$ T cells, and dendritic cells. The “gene” module of TIMER was used to analyze the correlations between ANXA9 expression and the six infiltrating immune cells in GC.

**The analysis of ANXA9-related genes**

The differential expression analysis of the ANXA9 high and low expression groups was implemented using the “Limma” package (Ritchie et al., 2015). The differentially expressed genes (DEGs) were screened with the selection condition of $|\log_{2} \text{fold change (FC)}| > 1$ and $P$-value $< 0.05$. By calculating the correlation between ANXA9 expression and these DEGs, ANXA9-related genes were determined with a $|\text{correlation coefficient}| > 0.3$ and a $P$ value $< 0.05$. A network was constructed with ANXA9 and ANXA9-related genes. The pink ellipse represented a positive correlation with the ANXA9, and the purple ellipse represented a negative correlation with ANXA9.

The ANXA9-related genes were added to the Database for Annotation, Visualization and Integrated Discovery (DAVID) online tool (https://david.ncifcrf.gov/) for GO and KEGG enrichment analysis.

**Statistical analysis**

All data in this study was analyzed using R software. The relationship of ANXA9 among clinicopathological characteristics in GC patients was compared using the Wilcox.test. The survival analysis of different groups was performed using the K-M analysis with the log-rank test. In all analyses, $P$ values $< 0.05$ were considered statistically significant.
RESULTS

The expression and diagnostic value of ANXA9 in GC

To investigate the differences of ANXA9 expression between tumor and normal samples, the ANXA9 mRNA expression levels in 33 human cancers were examined using the GEPIA database. The results showed that ANXA9 expression was significantly increased in breast invasive carcinoma (BRCA), colon adenocarcinoma (COAD), stomach adenocarcinoma (STAD), and rectum adenocarcinoma (READ) compared with the normal tissues. However, low expression of ANXA9 was found in esophageal carcinoma (ESCA), head and neck squamous cell carcinoma (HNSC), kidney chromophobe (KICH), kidney renal clear cell carcinoma (KIRC), kidney renal papillary cell carcinoma (KIRP), skin cutaneous melanoma (SKCM), testicular germ cell tumors (TGCT), uterine corpus endometrial carcinoma (UCEC), and uterine carcinosarcoma (UCS) (Fig. 1A, P < 0.05). ANXA9 expression in GC and normal samples was analyzed using the transcriptome data from the TCGA database. Consistently, these results revealed that ANXA9 expression was in GC patients (Fig. 1B, P < 0.05). The expression of ANXA9 was also analyzed in four GEO microarray series, and the results indicated a large increase of ANXA9 expression in GC patients (Figs. 1C–1F, P < 0.05). Based on the data from the HPA database, deeper staining levels of ANXA9 was observed in GC tissues compared to that of normal tissues, revealing a higher protein expression in GC (Figs. 1G–1J).

Importantly, ROC curves showed that the AUC of the ANXA9 expression levels reached 0.655, 0.828, 0.645, 0.809 and 0.774 in the TCGA, GSE13861, GSE13911, GSE19826, and GSE79973 datasets, respectively, suggesting that ANXA9 expression levels could be used to distinguish GC patients from normal individuals (Figs. 2A–2E). Collectively, these results illustrated that ANXA9 was both elevated in GC and has diagnostic value, suggesting that ANXA9 has an important regulatory role in the progression of GC.

Relationship of ANXA9 expression and clinicopathological characteristics of GC patients

Having demonstrated that the expression of ANXA9 was elevated in GC patients, we then explored the relationship of ANXA9 expression and clinicopathological characteristics in GC patients. The results of the TCGA database analysis revealed that 51–70-year old GC patients had a higher ANXA9 level than 71–90-year-old GC patients (Fig. 3A, P < 0.05). Moreover, an elevated expression of ANXA9 was observed in male GC patients (Fig. 3B, P < 0.05). ANXA9 expression was not associated, however, with the pathological stage and TNM stage of GC patients in the TCGA database (Figs. 3C–3F, P > 0.05). We also tested the differences in the expression of ANXA9 between Carcinoma diffuse type GC and Adenocarcinoma intestinal type GC based on the Lauren classification. Patients with Adenocarcinoma intestinal type GC had a higher expression level than patients with Carcinoma diffuse type GC (Fig. 3G, P = 0.022).
The relationship between ANXA9 expression and clinicopathological characteristics was analyzed using the UALCAN online database. In the histological subtype analysis, a significant up-regulation of ANXA9 was observed in both IntAdenoNOS and IntAdenoTubular GC patients (Fig. 4A, P < 0.05). We also found that the expression level of ANXA9 was significantly up-regulated in patients with GC classified as Grade 2 compared with the normal samples (Fig. 4B, P < 0.05). In addition, increased ANXA9 expression was observed in TP53-mutant GC patients (Fig. 4C, P < 0.05). However, no significant correlation was found between ANXA9 expression and the age, race, gender, primary tumor, H.pylori infection status, metastasis status, and pathological stage of GC patients (Figs. 4D–4J, P > 0.05). Taken together, these results indicated that high ANXA9 expression is widely correlated with different clinicopathological characteristics of GC.

The prognostic value of ANXA9 in GC
To further explore whether the ANXA9 was correlated with the survival of patients with GC, we compared the OS between the ANXA9 high expression and ANXA9 low expression groups using the K-M analysis. Notably, the results showed that the GC
patients with a high expression of ANXA9 had a higher survival probability (Figs. 5A–5C, \(P < 0.05\)), demonstrating that ANXA9 expression was associated with the prognosis of GC patients. We also observed a correlation between ANXA9 expression and OS in other cancers using the UALCAN database. Interestingly, the higher expression of ANXA9 was correlated with lower OS of UCEC patients (Fig. S1), which was just the opposite of the results for GC patients.

**Figure 2** ROC curves showed that ANXA9 could distinguish the GC patients from normal individuals. (A–E) ROC curves in the TCGA database (A) and GSE13861 (B), GSE13911 (C), GSE19826 (D), and GSE79973 (E) datasets.
Gene set enrichment analysis

To investigate the biological functions of ANXA9 in GC, GSEA was carried out to clarify the GO terms and the KEGG pathways that ANXA9 was involved in. Based on the enrichment score, we listed the top 10 most relevant biological processes and pathways.
Figure 4 Relationship of ANXA9 expression and clinicopathological characteristics of GC patients based on the UALCAN online database. (A–I) the mRNA expression levels between different histological subtypes (A), tumor grade (B), TP53 mutation status (C), age (D), race (E), gender (F), sample types (G), H. pylori infection status (H), nodal metastasis status (I), and tumor stage based on the UALCAN online database.

DOI: 10.7717/peerj.12605/fig-4
The GO results showed that AXONEMAL DYNEIN COMPLEX ASSEMBLY, AXONEME ASSEMBLY, CILIARY TRANSITION ZONE, CORNIFICATION, CORNIFIED ENVELOPE, INTRACILIARY TRANSPORT, INTRACILIARY TRANSPORT INVOLVED IN CILIUM ASSEMBLY, INTRACILIARY TRANSPORT PARTICLE, KERATINIZATION were enriched in the ANXA9 high expression group (Fig. 6A). Low expression of ANXA9 was associated with immune-related biological functions, including CHEMOKINE BINDING, CYTOSOLIC RIBOSOME, LEUKOCYTE ADHESION TO VASCULAR ENDOTHELIAL CELL, PHAGOCYTIC CUP, POSITIVE REGULATION OF LEUKOCYTE CELL-CELL ADHESION, POSITIVE T CELL SELECTION, RESPONSE TO CHEMOKINE, and T CELL SELECTION (Fig. 6B). Interestingly, KEGG analysis demonstrated that the genes in both the ANXA9 high expression and ANXA9 low expression groups participated in STEROID BIOSYNTHESIS, HEMATOPOIETIC CELL LINEAGE, and RIBOSOME signal pathways. The comprehensive analysis of these results indicated that ANXA9 plays a regulatory role in the progression of GC.
Correlation between ANXA9 expression and immune infiltration levels in GC

Based on the results of the functional enrichment, we observed that ANXA9 is related to the immune response in GC. Therefore, we further calculated the number of immune cells in each GC sample using ssGSEA. A total of 21 immune-response gene sets were significantly different between the ANXA9 high expression and ANXA9 low expression groups. These gene sets include APC_co_inhibition, B_cells, CCR, CD8_T_cells, Checkpoint, Cytolytic_activity, DCs, HLA, Inflammation_promoting, Neutrophils, NK_cells, pDCs, T_cell_co_inhibition, T_cell_co_stimulation, T_helper_cells, Th1_cells, Th2_cells, TIL, Treg and Type_II_IFN_Response. The expression of these 21 immune-response gene sets were significantly increased in the ANXA9 low expression group (Fig. 7A, \( P < 0.05 \)). We then investigated the correlation between ANXA9 expression and immune infiltration in the TIMER database. As shown in Fig. 7B, ANXA9 expression was significantly negatively correlated with the infiltration level of CD8+ T cells.
The ANXA9 methylation and copy number variation (CNV) analyses

DNA methylation is the main epigenetic mechanism for regulating gene expression in the tumorigenesis and development (Maeder et al., 2013). We used MEXPRESS to analyze whether the expression of ANXA9 was related to its methylation. Figure 8 showed that there was a negative correlation between the ANXA9 expression and the methylation of CpG and promoter regions. 4 abnormal methylation sites with cut-off value of correlation coefficient $<-0.3$ were observed including cg25468058 (Cor = −0.503), cg04144222 (Cor = −0.523), cg07337598 (Cor = −0.349), and cg13912599 (Cor = −0.321). The ANXA9 expression positively correlated with its CNV change (Cor = 0.240, $P < 0.0001$). Our results showed that the CNV change of ANXA9 occurred in GC patients.

Analysis of ANXA9-related genes

To further investigate the role of ANXA9 in GC, we identified 179 ANXA9-related genes with the criteria $|\text{Cor}| > 0.3$, $P < 0.05$ based on the DEGs between ANXA9 high and ANXA9 low expression groups (Fig. 9A, Table S1). From the PPI network, we retrieved 162 significantly positively related genes and 17 significantly negatively related genes, which were utilized for GO and KEGG enrichment analysis (Figs. 9B and 9C). The enriched biological process (BP) terms were actin filament bundle assembly, skeletal...
Figure 9 The analysis of ANXA9-related genes. (A) Volcano plot of the DEGs between the ANXA9 high and ANXA9 low expression groups. (B) The PPI network of ANXA9 and ANXA9-related genes. (C) The GO function enriched by ANXA9-related genes.
muscle contraction, cell-cell adhesion, Rho protein signal transduction, and cellular response to hyperoxia. The ANXA9-related genes were associated with cellular components (CC) terms, such as endoplasmic reticulum membrane, primary cilium, cell-cell adherens junction, extracellular exosome, and endoplasmic reticulum-Golgi intermediate compartment membrane. The molecular function (MF) terms associated with ANXA9-related genes were microtubule motor activity, Rho guanyl-nucleotide exchange factor activity, actin filament binding, and cadherin binding involved in cell-cell adhesion were significantly enriched. However, there was no significant enrichment of KEGG pathways. The data indicated that ANXA9-related genes may also play a role in GC progression.

**DISCUSSION**

GC is a common malignancy of the digestive system. Although great advances have been made in the diagnosis and treatment of GC, the prognosis of GC patients is still terrible (Miller et al., 2019). An increasing number of studies have noted the superiority of molecular therapy in the treatment of GC (Xu et al., 2018; Shitara et al., 2019). Therefore, it is urgent to screen novel biomarkers to increase early diagnosis and treatment of GC.

To the best of our knowledge, our study was the first to systematically explore the role of ANXA9 in GC. We initially investigated the expression of ANXA9 in pan-cancer samples using the GEPIA site, and found that ANXA9 expression was up-regulated in most cancer samples, including GC samples, when compared to normal samples, as well as GC (Fig. 1A). The bioinformatics analysis of data from the TCGA and GEO databases also suggested that ANXA9 expression was significantly increased in GC samples (Figs. 1B–1G). Interestingly, the analyses we performed using the UALCAN database revealed that ANXA9 expression was significantly related to GC grade, TP53 mutation and histological subtype. More importantly, the K-M analysis suggested that ANXA9 expression was associated with the prognosis of GC patients (Figs. 5A–5C). Consistent with our results, it has been suggested that ANXA9 is associated with the prognosis of breast cancer and colorectal cancer (Xiao et al., 2019; Miyoshi et al., 2014; Yu et al., 2018). ANXA9 could also affect the pathogenesis of HPV-Negative head and neck squamous cell carcinomas (Salom et al., 2019) and regulate the enhanced cisplatin-resistance in ovarian carcinoma (Kou et al., 2021). Notably, ANXA9 expression was higher in GC samples compared to normal samples and the high ANXA9 expression group had a better OS rate (Figs. 1C–1G and 5A–5C), which is the opposite of what we see in colorectal cancer (Yu et al., 2018) and UCEC (Fig. S1). We speculate that this difference of ANXA9 role among GC, UCEC and colorectal cancer may be due to the dual roles of genes in cancer pathogenesis. For example, reducing NLK expression can suppress cell growth and tumorigenesis in some tumors, but can produce the opposite effects in other tumors (Li et al., 2018). Similarly, YY1 is up-regulated in many cancers, while sometimes is down-regulated in other cancers (Hays & Bonavida, 2019). PA2G4 also has opposite roles in prostate cancer and colon cancer (Nguyen et al., 2018). On the other hand, this difference of ANXA9 role between GC and colorectal cancer may be caused by the heterogeneity of GC and colorectal cancer. Research suggests that the factors and
molecular pathways involved in GC tumorigenesis are different from colorectal cancer (Park et al., 2017). For example, alterations of p53 or missing genes may play different roles in the progression of GC compared to colorectal cancers (Kataoka et al., 2000). In addition, hepatic metastases from GC present more systematic and aggressive tumor behavior than those from colorectal cancer (Oguro et al., 2016). Furthermore, it has been revealed that MDR1 mRNA levels in GC cells are significantly lower than those in colon cancer cells, which means they have different epigenetic regulations such as DNA methylation and/or histone deacetylation in GC and colon cancer (Lee et al., 2008). Particularly, ANXA may play a multifaceted and possibly distinctive role in different cancers. For instance, annexin A7 acts as a tumor suppressor in prostate cancer, melanoma and glioblastoma (Srivastava et al., 2001; Hung & Howng, 2003; Kataoka et al., 2000), whereas annexin A7 can accelerate the progression of liver, colorectal, and breast cancers (Srivastava et al., 2004; Srivastava et al., 2007; Sun et al., 2009). Thus, given the expression pattern and prognostic impact of ANXA9, we speculated that the ANXA9 might not be related to the occurrence of GC, but might affect the development of GC. Namely, the occurrence of GC might induce the up-regulation of ANXA9 expression resulting in a protective effect on human body. It also has been noted that CA12 expression is higher in breast cancer tissues and a high CA12 expression in breast cancer patients is associated with better OS (Li et al., 2019). In addition, Li et al. (2020) also found that BUB1 was highly expressed in gastric cancer compared with normal gastric tissue and a K-M survival analysis showed that the OS time was prolonged in gastric cancer patients with a high expression of BUB1. Collectively, these findings suggested that ANXA9 might play an important role in GC, and that ANXA9 could be selected as a biomarker for the diagnosis and treatment of GC.

The genes in ANXA9 high expression group were mainly enriched in an axonemal dynein complex (Fig. 6A). It has been suggested that ANXA9 is found in protein complexes containing periplakin, a cytoskeletal linker protein belonging to the plakin family (Boczonadi & Määttä, 2012). Moreover, ANXA9 has been reported to participate in the bone metastasis of breast cancer. Thus, we speculated that ANXA9 might be involved in the bone metastasis of GC. On the other hand, the genes in ANXA9 low expression group were primarily involved in immune-related biological processes, such as chemokine binding and T cell selection (Fig. 6B). Therefore, we speculated that ANXA9 might also regulate GC prognosis by influencing the immune response. Consistent with our hypothesis, patients in ANXA9 low expression group showed higher proportions of infiltrating immune cells (Fig. 7A), indicating that the poor OS of patients in the ANXA9 low expression group might be caused by immunosuppressive milieu (Cao et al., 2020) and increasing the expression of ANXA9 could protect against the immunosuppressive environment of GC resulting in an improved GC prognosis (Li et al., 2020). Notably, we found that ANXA9 expression was significantly negatively correlated with the infiltration level of CD8+ T cells (Figure 7B). It has been suggested that CD8+ T cells could produce interferon Gamma (IFNG) and introduce the expression of PD-1/PD-L1, resulting in antitumor immunity (Ribas & Hu-Lieskovan, 2016). Therefore, these finding
implies that the ANXA9 low expression group might have a stronger tumor immnosuppressive environment.

We further investigated the DNA methylation level of ANXA9 and the correlation between CNV and expression of ANXA9 expression, and found that there was a negative correlation between ANXA9 expression and the methylation of CpG and promoter regions, and ANXA9 expression positively correlated with its CNV (Fig. 8). Therefore, the DNA methylation and CNV might affect the expression of ANXA9.

Ultimately, we also found ANXA9 might affect the survival of GC by affecting ANXA9-related genes, which can regulating actin filament bundle assembly, skeletal muscle contraction, cell-cell adhesion, Rho protein signal transduction, and cellular response to hyperoxia.

CONCLUSION

This study found that ANXA9 expression significantly increased in GC samples compared to normal tissues and the ANXA9 high expression group showed a higher survival probability. Moreover, the present study also revealed that increasing the expression of ANXA9 might improve GC prognosis by protecting against the immnosuppressive environment of GC. Furthermore, the expression change of ANXA9 might be caused by the DNA methylation and CNV ANAXA9. In a word, this study revealed the potential role of ANXA9 in GC immunology and prognosis, which might contribute to the further understanding of the possible molecular mechanism of GC and lead to improved GC treatments. However, more studies are needed to further illustrate the specific regulatory mechanisms of ANXA9.

ABBREVIATIONS

GC  gastric cancer
GEPIA Gene Expression Profiling Interactive Analysis
GEO Gene Expression Omnibus
Wilcoxon test Wilcoxon sign-ranked test
ROC receiver operating characteristic
TCGA The Cancer Genome Atlas
TIMER Tumor Immune Estimation Resource
ANXA Annexin A
ANXA9 Annexin A9
GTEx Genotype-Tissue Expression
AUC area under the curve
HPA 2.4. Human Protein Atlas
OS overall survival
K-M Kaplan-Meier
GSEA Gene set enrichment analysis
ssGSEA single-sample gene set enrichment
DEGs differentially expressed genes
BRCA Breast Invasive Carcinoma
COAD  Colon Adenocarcinoma
STAD  Stomach Adenocarcinoma
READ  Rectum adenocarcinoma
ESCA  Esophageal carcinoma
HNSC  Head and Neck squamous cell carcinoma
KICH  Kidney Chromophobe
KIRC  Kidney renal clear cell carcinoma
KIRP  Kidney renal papillary cell carcinoma
SKCM  Skin Cutaneous Melanoma
TGCT  Testicular Germ Cell Tumors
UCEC  Uterine Corpus Endometrial Carcinoma
UCS  Uterine Carcinosarcoma
CNV  copy number variation

**ADDITIONAL INFORMATION AND DECLARATIONS**

**Funding**
The authors received no funding for this work.

**Competing Interests**
The authors declare that they have no competing interests.

**Author Contributions**
- Tongtong Zhang performed the experiments, analyzed the data, prepared figures and/or tables, authored or reviewed drafts of the paper, and approved the final draft.
- Suyang Yu performed the experiments, analyzed the data, prepared figures and/or tables, authored or reviewed drafts of the paper, and approved the final draft.
- Shipeng Zhao conceived and designed the experiments, prepared figures and/or tables, and approved the final draft.

**Data Availability**
The following information was supplied regarding data availability:

The datasets used in the present study are available at GEO: GSE13911, GSE19826, GSE79973.

The RNA-seq transcriptome data and corresponding clinical information of STAD cohort was retrieved from TCGA (https://portal.gdc.cancer.gov/).

**Supplemental Information**
Supplemental information for this article can be found online at http://dx.doi.org/10.7717/peerj.12605#supplemental-information.
REFERENCES

Asplund A, Edqvist PH, Schwenk JM, Pontén F. 2012. Antibodies for profiling the human proteome-The Human Protein Atlas as a resource for cancer research. Proteomics 12(13):2067–2077 DOI 10.1002/pmic.201100504.

Boczonadi V, Määttä A. 2012. Annexin A9 is a periplakin interacting partner in membrane-targeted cytoskeletal linker protein complexes. FEBS Letters 586(19):3090–3096 DOI 10.1016/j.febslet.2012.07.057.

Boudhraa Z, Bouchon B, Viallard C, D’Incan M, Degoul F. 2016. Annexin A1 localization and its relevance to cancer. Clinical Science (Lond) 130(4):205–220 DOI 10.3322/caac.21338.

Cao R, Yuan L, Ma B, Wang G, Tian Y. 2020. Immune-related long non-coding RNA signature identified prognosis and immunotherapeutic efficiency in bladder cancer (BLCA). Cancer Cell International 20:276 DOI 10.1186/s12935-020-01362-0.

Chandrashekar DS, Bashel B, Balasubramanya SAH, Creighton CJ, Ponce-Rodriguez I, Chakravarthi BVSK, Varambally S. 2017. UALCAN: a portal for facilitating tumor subgroup gene expression and survival analyses. Neoplasia 19(8):649–658 DOI 10.1016/j.neo.2017.05.002.

Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, Jemal A, Yu XQ, He J. 2016. Cancer statistics in China, 2015. CA-A Cancer Jurnal for Clinicians 66(2):115–132 DOI 10.3322/caac.21338.

Chon SH, Berlth F, Plum PS, Herbold T, Alakus H, Kleinert R, Moenig SP, Bruns CJ, Hoelscher AH, Meyer HJ. 2017. Gastric cancer treatment in the world: Germany. Transl Gastroenterol Hepatol 26(2):53 DOI 10.21037/tgh.2017.05.07.

Correa P. 2016. Gastric cancer: overview. Gastroenterology Clinics of North America 42(2):211–217 DOI 10.1016/j.gtc.2013.01.002.

Edgar R, Domrachev M, Lash AE. 2002. Gene expression omnibus: NCBI gene expression and hybridization array data repository. Nucleic Acids Research 30:207–210 DOI 10.1093/nar/30.1.207.

Goebeler V, Ruhe D, Gerke V, Rescher U. 2003. Atypical properties displayed by annexin A9, a novel member of the annexin family of Ca(2+) and lipid binding proteins. FEBS Letters 546(2–3):359–364 DOI 10.1016/s0014-5793(03)00634-3.

Hays E, Bonavida B. 2019. YY1 regulates cancer cell immune resistance by modulating PD-L1 expression. Drug Resistant Update 43:10–28 DOI 10.1016/j.drup.2019.04.001.

Heagerty PJ, Lumley T, Pepe MS. 2000. Time-dependent ROC curves for censored survival data and a diagnostic marker. Biometrics 56(2):337–344 DOI 10.1111/j.0006-341x.2000.00337.x.

Hung KS, Howng SL. 2003. Prognostic significance of annexin VII expression in glioblastomas multiforme in humans. Journal of Neurosurgery 99(5):886–892 DOI 10.3171/jns.2003.99.5.0886.

Hänzelmann S, Castelo R, Guinney J. 2013. GSVA: gene set variation analysis for microarray and RNA-seq data. BMC Bioinformatics 14:7 DOI 10.1186/1471-2105-14-7.

Kataoka TR, Ito A, Asada H, Watabe K, Nishiyama K, Nakamoto K, Itami S, Yoshikawa K, Ito M, Nojima H, Kitamura Y. 2000. Annexin VII as a novel marker for invasive phenotype of malignant melanoma. Japanese Journal of Cancer Research 91(1):75–83 DOI 10.1111/j.1349-7006.2000.tb00862.x.

Kataoka M, Okabayashi T, Johira H, Nakatani S, Nakashima A, Takeda A, Nishizaki M, Orita K, Tanaka N. 2000. Aberration of p53 and DCC in gastric and colorectal cancer. Oncology Reports 7(1):99–103.

Kim C, Mulder K, Spratlin J. 2014. How prognostic and predictive biomarkers are transforming our understanding and management of advanced gastric cancer. Oncologist 19(10):1046–1055 DOI 10.1634/theoncologist.2014-0006.
Kou X, Ding H, Li L, Chao H. 2021. Hsa-miR-105-1 regulates cisplatin-resistance in ovarian carcinoma cells by targeting ANXA9. *Analytical Cellular Pathology* **2021**:6662486 DOI 10.1155/2021/6662486.

Lauritzen SP, Boye TL, Nylandsted J. 2015. Annexins are instrumental for efficient plasma membrane repair in cancer cells. *Seminars in Cell & Developmental Biology* **45**:32–38 DOI 10.1016/j.semcdb.2015.10.028.

Lee TB, Park JH, Min YD, Kim KJ, Choi CH. 2008. Epigenetic mechanisms involved in differential MDR1 mRNA expression between gastric and colon cancer cell lines and rationales for clinical chemotheray. *BMC Gastroenterology* **8**:33 DOI 10.1186/1471-230X-8-33.

Li T, Fan J, Wang B, Traugh N, Chen Q, Liu JS, Li B, Liu XS. 2017. TIMER: a web server for comprehensive analysis of tumor-infiltrating immune cells. *Cancer Research* **77**(21):e108–e110 DOI 10.1158/0008-5472.CAN-17-0307.

Li X, He J, Yu M, Zhang W, Sun J. 2020. [BUB1 gene is highly expressed in gastric cancer: analysis based on Oncomine database and bioinformatics]. *Nan Fang Yi Ke Da Xue Xue Bao* **40**(5):683–692 DOI 10.12122/j.issn.1673-4254.2020.05.11.

Li Y, Lei B, Zou J, Wang W, Chen A, Zhang J, Fu Y, Li Z. 2019. High expression of carbonic anhydrase 12 (CA12) is associated with good prognosis in breast cancer. *Neoplasma* **66**(3):420–426 DOI 10.4149/neo_2018_180819N624.

Li SZ, Zeng F, Li J, Shu QP, Zhang HH, Xu J, Ren JW, Zhang XD, Song XM, Du RL. 2018. Nemo-like kinase (NLK) primes colorectal cancer progression by releasing the E2F1 complex from HDAC1. *Cancer Letters* **431**:43–53 DOI 10.1016/j.canlet.2018.05.032.

Lordick F, Kang YK, Chung HC, Salman P, Oh SC, Bodoky G, Kurteva G, Volovat C, Moiseyenko VM, Gorbunova V, Park JO, Sawaki A, Celik I, Gõte H, Melezinková H, Moehler M, Arbeitsgemeinschaft Internistische Onkologie and EXPAND Investigators. 2013. Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial. *Lancet Oncology* **14**(6):490–499 DOI 10.1016/S1470-2045(13)70102-5.

Luebeck EG, Curtius K, Jeon J, Hazelton WD. 2013. Impact of tumor progression on cancer incidence curves. *Cancer Research* **73**(3):1086–1096 DOI 10.1158/0008-5472.CAN-12-2198.

Maeda K, Chung YS, Ogawa Y, Takatsuaka S, Kang SM, Ogawa M, Sawada T, Sowa M. 1996. Prognostic value of vascular endothelial growth factor expression in gastric carcinoma. *Cancer* **77**(5):858–863 DOI 10.1002/(sici)1097-0142(19960301)77:5<858::aid-cncr8>3.0.co;2-a.

Maeder MI, Angstman JF, Richardson ME, Linder SJ, Cascio VM, Tsai SQ, Ho QH, Sander JD, Reyon D, Bernstein BE, Costello JF, Wilkinson MF, Joung JK. 2013. Targeted DNA demethylation and activation of endogenous genes using programmable TALE-TET1 fusion proteins. *Nature Biotechnology* **31**(12):1137–1142 DOI 10.1038/nbt.2726.

Miller KD, Nogueira L, Mariotto AB, Rowland JH, Yabroff KR, Alfano CM, Jemal A, Kramer JL, Siegel RL. 2019. Cancer treatment and survivorship statistics, 2019. *CA-A Cancer Journal for Clinicians* **69**(5):363–385 DOI 10.3322/caac.21565.

Miyoshi N, Yamamoto H, Mimori K, Yamashita S, Miyazaki S, Nakagawa S, Ishii H, Noura S, Ohue M, Yano M, Doki Y, Mori M. 2014. ANXA9 gene expression in colorectal cancer: a novel marker for prognosis. *Oncology Letters* **8**(5):2313–2317 DOI 10.3892/ol.2014.2477.

Morgan RO, Bell DW, Testa JR, Fernandez MP. 1999. Human annexin 31 genetic mapping and origin. *Gene* **227**(1):33–38 DOI 10.1016/s0378-1119(98)00597-6.

Nakashima Y, Nahar S, Miyagi-Shiohira C, Kinjo T, Kobayashi N, Kitamura S, Saitoh I, Watanabe M, Fujita J, Noguchi H. 2019. Identification of proteins differentially expressed by
adipose-derived mesenchymal stem cells isolated from immunodeficient mice. *International Journal of Molecular Sciences* 20(11):2672 DOI 10.3390/ijms20112672.

Nguyen DQ, Hoang DH, Nguyen Vo TT, Huynh V, Ghoda L, Marcucci G, Nguyen LXT. 2018. The role of ErbB3 binding protein 1 in cancer: friend or foe? *Journal of Cellular Physiology* 233:9110–9120 DOI 10.1002/jcp.26951.

Oguro S, Imamura H, Yoshimoto J, Ishizaki Y, Kawasaki S. 2016. Liver metastases from gastric cancer represent systemic disease in comparison with those from colorectal cancer. *Journal of Hepato-Biliary-Pancreatic Sciences* 23(6):324–332 DOI 10.1002/jhbp.343.

Park SM, Lee J, Kim YA, Chang YJ, Kim MS, Shim YM, Zo JI, Yun YH. 2017. Factors related with colorectal and stomach cancer screening practice among disease-free lung cancer survivors in Korea. *BMC Cancer* 17(1):600 DOI 10.1186/s12885-017-3583-z.

Qi H, Liu S, Guo C, Wang J, Greenaway FT, Sun MZ. 2015. Role of annexin A6 in cancer. *Oncology Letters* 10(4):1947–1952 DOI 10.3892/ol.2015.3498.

Ribas A, Hu-Lieskovan S. 2016. What does PD-L1 positive or negative mean? *Journal of Experimental Medicine* 213(13):2835–2840 DOI 10.1084/jem.20161462.

Ritchie ME, Phipson B, Wu D, Hu Y, Law CW, Shi W, Smyth GK. 2015. limma powers differential expression analyses for RNA-sequencing and microarray studies. *Nucleic Acids Research* 43(7):e47 DOI 10.1093/nar/gkv007.

Salom C, Álvarez-Teijeiro S, Fernández MP, Morgan RO, Alfonca E, Vallina A, Lorz C, de Villalain L, Fernández-García MS, Rodrigo JP, García-Pedrero JM. 2019. Frequent alteration of annexin A9 and A10 in HPV-negative head and neck squamous cell carcinomas: correlation with the histopathological differentiation grade. *Journal of Clinical Medicine* 8(2):229 DOI 10.3390/jcm8020229.

Shitara K, Iwata H, Takahashi S, Tamura K, Park H, Modi S, Tsurutani J, Kadowaki S, Yamaguchi K, Iwasa S, Saito K, Fujisaki Y, Sugihara M, Shahidi J, Doi T. 2019. Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive gastric cancer: a dose-expansion, phase 1 study. *Lancet Oncology*. *Lancet Oncology* 20(6):827–836 DOI 10.1016/S1470-2045(19)30088-9.

Smid M, Wang Y, Klijn JG, Sieuwerts AM, Zhang Y, Atkins D, Martens JW, Foekens JA. 2006. Genes associated with breast cancer metastatic to bone. *Journal of Clinical Oncology* 24(15):2261–2267 DOI 10.1200/JCO.2005.03.8802.

Song Z, Wu Y, Yang J, Yang D, Fang X. 2017. Progress in the treatment of advanced gastric cancer. *Tumour Biology* 39(7):1010428317714626 DOI 10.1177/1010428317714626.

Srivastava M, Bubendorf L, Raffeld M, Bucher C, Torhorst J, Sauter G, Olsen C, Kallioniemi OP, Eidelberg O, Pollard HB. 2004. Prognostic impact of ANX7-GTPase in metastatic and HER2-negative breast cancer patients. *Clinical Cancer Research* 10(7):2344–2350 DOI 10.1158/1078-0432.ccr-03-0278.

Srivastava M, Bubendorf L, Srikantan V, Fossom L, Nolan L, Glasman M, Leighton X, Fehle W, Pittaluga S, Raffeld M, Koivisto P, Willi N, Gasser TC, Kononen J, Sauter G, Kallioniemi OP, Srivastava S, Pollard HB. 2001. ANX7, a candidate tumor suppressor gene for prostate cancer. *Proceedings of the National Academy of Sciences of the United States of America* 98(8):4575–4580 DOI 10.1073/pnas.071055798.

Srivastava M, Torosyan Y, Raffeld M, Eidelberg O, Pollard HB, Bubendorf L. 2007. ANXA7 expression represents hormone-relevant tumor suppression in different cancers. *International Journal of Cancer* 121(12):2628–2636 DOI 10.1002/ijc.23008.

Sun MZ, Liu S, Tang J, Wang Z, Gong X, Sun C, Greenaway F. 2009. Proteomics analysis of two mice hepatocarcinoma ascites syngeneic cell lines with high and low lymph node metastasis rates
provide potential protein markers for tumor malignancy attributes to lymphatic metastasis. *Proteomics* **9**(12):3285–3302 DOI 10.1002/pmic.200701002.

**Tang Z, Li C, Kang B, Gao G, Li C, Zhang Z. 2017.** GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses. *Nucleic Acids Research* **45**(W1):W98–W102 DOI 10.1093/nar/gkx247.

**Tomczak K, Czerwińska P, Wiznerowicz M. 2015.** The cancer genome atlas (TCGA): an immeasurable source of knowledge. *Contemporary Oncology* **19**(1A):A68–A77 DOI 10.5114/wo.2014.47136.

**Tsukanov VV, Butorin NN, Maady AS, Shtygasheva OV, Amelchugova OS, Tonkikh JL, Fassan M, Rugge M. 2011.** Helicobacter pylori infection, intestinal metaplasia, and gastric cancer risk in Eastern Siberia. *Helicobacter* **16**(2):107–112 DOI 10.1111/j.1523-5378.2011.00827.x.

**Xiao B, Hang J, Lei T, He Y, Kuang Z, Wang L, Chen L, He J, Zhang W, Liao Y, Sun Z, Li L. 2019.** Identification of key genes relevant to the prognosis of ER-positive and ER-negative breast cancer based on a prognostic prediction system. *Molecular Biology Reports* **46**(2):2111–2119 DOI 10.1007/s11033-019-04663-4.

**Xu B, Huang C, Yang X, Li X, Li L, Ding Y. 2018.** Significance and prognostic role of human epidermal growth factor receptor 2 and RAB1A expression in gastric cancer. *Oncology Letters* **15**(4):5185–5192 DOI 10.3892/ol.2018.7992.

**Yu S, Bian H, Gao X, Gui L. 2018.** Annexin A9 promotes invasion and metastasis of colorectal cancer and predicts poor prognosis. *International Journal of Molecular Medicine* **41**(4):2185–2192 DOI 10.3892/ijmm.2018.3432.